# EDGAR Filing Document

**Accession Number:** 0001355250
**File Stem:** 0001477932-23-001052
**Filing Date:** 2023-2
**Character Count:** 10895
**Document Hash:** 6424ad2a9f3b0c6c3d5c7f020b8efea4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-23-001052.hdr.sgml**: 20230215

**ACCESSION NUMBER**: 0001477932-23-001052

**CONFORMED SUBMISSION TYPE**: NT 10-Q

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230215

**DATE AS OF CHANGE**: 20230215

**EFFECTIVENESS DATE**: 20230215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Innovation Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001355250
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 300565645
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** NT 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37357
- **FILM NUMBER:** 23633616

**BUSINESS ADDRESS:**
- **STREET 1:** 301 EDGEWATER PLACE
- **STREET 2:** SUITE 100
- **CITY:** WAKEFIELD
- **STATE:** MA
- **ZIP:** 01880
- **BUSINESS PHONE:** 978-921-4125

**MAIL ADDRESS:**
- **STREET 1:** 301 EDGEWATER PLACE
- **STREET 2:** SUITE 100
- **CITY:** WAKEFIELD
- **STATE:** MA
- **ZIP:** 01880

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cellceutix CORP
- **DATE OF NAME CHANGE:** 20080515

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EconoShare, Inc.
- **DATE OF NAME CHANGE:** 20060306

---

| | |
|:---|:---|
|  | OMB APPROVAL |
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549** <br>**FORM 12b-25**<br>**NOTIFICATION OF LATE FILING** | OMB Number: 3235-0058<br> Expires: April 30, 2025<br> Estimated average burden<br> hours per response . . . . . . 2.50 |
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549** <br>**FORM 12b-25**<br>**NOTIFICATION OF LATE FILING** | SEC FILE NUMBER<br> **001-37357** |
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549** <br>**FORM 12b-25**<br>**NOTIFICATION OF LATE FILING** | CUSIP NUMBER<br> **45782D100** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *(Check one):* | ☐ Form 10-K | ☐ Form 20-F | ☐ Form 11-K | ☒ Form 10-Q | ☐ Form 10-D |
|  | ☐ Form N-CEN | ☐ Form N-CSR |  |  |  |
|  | For Period Ended: **<u>December 31, 2022</u>**  | For Period Ended: **<u>December 31, 2022</u>**  | For Period Ended: **<u>December 31, 2022</u>**  | For Period Ended: **<u>December 31, 2022</u>**  | For Period Ended: **<u>December 31, 2022</u>**  |
|  | ☐ Transition Report on Form 10-K | ☐ Transition Report on Form 10-K | ☐ Transition Report on Form 10-K |  |  |
|  | ☐ Transition Report on Form 20-F | ☐ Transition Report on Form 20-F | ☐ Transition Report on Form 20-F |  |  |
|  | ☐ Transition Report on Form 11-K | ☐ Transition Report on Form 11-K | ☐ Transition Report on Form 11-K |  |  |
|  | ☐ Transition Report on Form 10-Q | ☐ Transition Report on Form 10-Q | ☐ Transition Report on Form 10-Q |  |  |
|  | For the Transition Period Ended: _____________________ | For the Transition Period Ended: _____________________ | For the Transition Period Ended: _____________________ | For the Transition Period Ended: _____________________ | For the Transition Period Ended: _____________________ |

---

**Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**<br>

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: __________________

**PART I — REGISTRANT INFORMATION**

---

| |
|:---|
| **Innovation Pharmaceuticals Inc.** |
| Full Name of Registrant |
| **N/A** |
| Former Name if Applicable |
| **301 Edgewater Place - Suite 100** |
| Address of Principal Executive Office *(Street and Number)* |
| **Wakefield, Massachusetts 01880** |
| City, State and Zip Code |

---

**PART II — RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III — NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

**Innovation Pharmaceuticals Inc. (the "Registrant") was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q (the "Quarterly Report") for the period ended December 31, 2022 (the "Reporting Period") by the February 14, 2023 filing due date applicable to non-accelerated filers due to a delay experienced by the Registrant in preparing its financial statements, and the Registrant's outside auditors in completing their review of the financial statements, in time to permit the Registrant to finalize the Quarterly Report and furnish the XBRL Interactive Data File exhibits required by Item 601(b)(101) of Regulation S-K by the filing due date. The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing due date.**

**PART IV — OTHER INFORMATION**

---

| | | | |
|:---|:---|:---|:---|
| (1) | Name and telephone number of person to contact in regard to this notification | Name and telephone number of person to contact in regard to this notification | Name and telephone number of person to contact in regard to this notification |
|  | **Leo Ehrlich** | **(978)** | **921-4125** |
|  | (Name) | (Area Code) | (Telephone Number) |
| (2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).  | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).  | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).  |
|  |  |  | ☒ Yes ☐ No |
| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? |
|  |  |  | ☒ Yes ☐ No |
|  | If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. | If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. | If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. |
|  | **The Registrant anticipates reporting net loss for the three and six months ended December 31, 2022 of $0.4 million and $1.8 million, respectively, as compared to $1.9 million and $3.9 million for the three and six months ended December 31, 2021, respectively, largely as a result of decreased research and development expense (approximately $33,000 and $0.8 million for the three and six months ended December 31, 2022, respectively, compared to $1.6 million and $3.2 million for the three and six months ended December 31, 2021, respectively), partially offset by other income of $0.2 million in the prior year periods and no such other income in the current year periods.** | **The Registrant anticipates reporting net loss for the three and six months ended December 31, 2022 of $0.4 million and $1.8 million, respectively, as compared to $1.9 million and $3.9 million for the three and six months ended December 31, 2021, respectively, largely as a result of decreased research and development expense (approximately $33,000 and $0.8 million for the three and six months ended December 31, 2022, respectively, compared to $1.6 million and $3.2 million for the three and six months ended December 31, 2021, respectively), partially offset by other income of $0.2 million in the prior year periods and no such other income in the current year periods.** | **The Registrant anticipates reporting net loss for the three and six months ended December 31, 2022 of $0.4 million and $1.8 million, respectively, as compared to $1.9 million and $3.9 million for the three and six months ended December 31, 2021, respectively, largely as a result of decreased research and development expense (approximately $33,000 and $0.8 million for the three and six months ended December 31, 2022, respectively, compared to $1.6 million and $3.2 million for the three and six months ended December 31, 2021, respectively), partially offset by other income of $0.2 million in the prior year periods and no such other income in the current year periods.** |

---

2<br>

**<u>Innovation Pharmaceuticals Inc.</u>**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date February 15, 2023 | By | */s/ Leo Ehrlich* |
|  |  | Leo Ehrlich |
|  |  | Chief Executive Officer<br> and Chief Financial Officer |

---

3<br>